|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Eye Institute (NEI) |
|---|---|
| Information provided by: | National Eye Institute (NEI) |
| ClinicalTrials.gov Identifier: | NCT00000148 |
Purpose
To assess the long-range outcomes of sequences of interventions involving trabeculectomy and argon laser trabeculoplasty in eyes that have failed initial medical treatment for glaucoma.
| Condition | Intervention | Phase |
|---|---|---|
|
Glaucoma |
Procedure: Argon Laser Trabeculoplasty Procedure: Trabeculectomy |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Efficacy Study |
| Study Start Date: | April 1988 |
In advanced glaucoma, medication alone no longer reduces intraocular pressure adequately, and the eye has field defects. Before 1980, some type of filtering surgery, such as trabeculectomy, was the usual method of intervention. Since then, laser trabeculoplasty has become a popular alternative. Sometimes the first intervention chosen succeeds in controlling pressure for many years; at other times, the success lasts only a few weeks or months. Because success is limited, some patients, over time, need to undergo a sequence of surgical interventions. Little is known about which sequence gives the best long-range outcome.
The Advanced Glaucoma Intervention Study (AGIS) is designed to provide a comprehensive assessment of the long-range outcomes of medical and surgical management in advanced glaucoma. The study uses visual function status to compare two intervention sequences in managing the disease.
Eligible eyes are randomly assigned to one of two intervention sequences: (1) trabeculectomy, followed by argon laser trabeculoplasty (ALT) should trabeculectomy fail, followed by a second trabeculectomy should ALT fail; or (2) ALT, followed by trabeculectomy should ALT fail, followed by another trabeculectomy should the first trabeculectomy fail. Antifibrotic agents may be used as an adjunct to trabeculectomy, but only in eyes with a previous history of invasive surgery. Eyes that fail the entire assigned sequence of interventions are managed at the discretion of the AGIS physician in collaboration with the patient.
Interventions are supplemented with medical treatment as needed. A total of 789 eyes with advanced glaucoma have been enrolled. All patients are being followed under a standardized protocol for a minimum of 5 years to determine degree of visual function loss, failure rates of interventions, rates of complications, and need for supplemental therapy.
After the initial intervention, followup examinations are scheduled at 1 week, 4 weeks, 3 months, 6 months, and every 6 months thereafter. After second and third interventions, followup examinations are scheduled at 1 and 4 weeks. Additional visits are scheduled as necessary for the management of the disease.
The primary outcome variable in AGIS is average percent of eyes with decrease of vision, where decrease of vision is a substantial decline of either visual field or visual acuity attributable to the effect of glaucoma. Secondary outcome variables include sustained decrease of vision, failure of interventions, number of prescribed glaucoma medications, and level of intraocular pressure. An ancillary study is assessing filtering bleb encapsulation.
Eligibility| Ages Eligible for Study: | 35 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Men and women between the ages of 35 and 80 with open-angle glaucoma that was not successfully controlled by medication were eligible for enrollment.
Contacts and Locations| United States, Connecticut | |
| Yale University School of Medicine, Yale Eye Center | |
| New Haven, Connecticut, United States | |
| United States, District of Columbia | |
| Georgetown University, University Ophthalmic Consultants of Washington, Eye Associates of Washington, D.C. | |
| Washington, District of Columbia, United States | |
| United States, Georgia | |
| Emory University, Emory Eye Center | |
| Atlanta, Georgia, United States | |
| Piedmont Hospital, Eye Consultants of Atlanta | |
| Atlanta, Georgia, United States | |
| United States, Illinois | |
| University of Illinois, Eye and Ear Infirmary | |
| Chicago, Illinois, United States | |
| Humana Health Plan Sykes Center | |
| Chicago, Illinois, United States | |
| United States, Maryland | |
| Washington Hospital Center, Washington Eye Physicians and Surgeons | |
| Chevy Chase, Maryland, United States | |
| United States, Michigan | |
| University of Michigan, W.K. Kellogg Eye Center | |
| Ann Arbor, Michigan, United States | |
| Sinai Hospital, Detroit, Franklin Eye Consultants | |
| Southfield, Michigan, United States | |
| United States, Ohio | |
| Ohio State University, Department of Ophthalmology, Ophthalmic Surgeons and Consultants | |
| Columbus, Ohio, United States | |
| United States, Pennsylvania | |
| Wills Eye Hospital, Glaucoma Service | |
| Philadelphia, Pennsylvania, United States | |
| United States, Virginia | |
| University of Virginia Medical Center, Department of Ophthalmology | |
| Charlottesville, Virginia, United States | |
| Medical College of Virginia, Department of Ophthalmology | |
| Richmond, Virginia, United States | |
More Information
| Study ID Numbers: | NEI-49 |
| Study First Received: | September 23, 1999 |
| Last Updated: | June 2, 2006 |
| ClinicalTrials.gov Identifier: | NCT00000148 History of Changes |
| Health Authority: | United States: Federal Government |
|
Glaucoma Eye Diseases Ocular Hypertension |